AlloVax® is a therapeutic anti-cancer vaccine consisting of CRCL as the source of tumor antigen and AlloStim® as an adjuvant. The intradermal injection of AlloVax® elicits tumor-specific Th1 immunity.
Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence. No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment. Innovative technology – proven and non-toxic. read more
Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options. Elicits a GVT-like mechanism without the GVHD toxicity. read more
Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.
Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist. read more